Litcius/Paper detail

LBA51 EMPOWER-Lung 3: Cemiplimab in combination with platinum doublet chemotherapy for first-line (1L) treatment of advanced non-small cell lung cancer (NSCLC)

Miranda Gogishvili, Tamar Melkadze, Tamta Makharadze, D. Giorgadze, Mikhail Dvorkin, Konstantin Penkov, К. К. Лактионов, Gia Nemsadze, M. Nechaeva, I. Rozhkova, Ewa Kalinka‐Warzocha, Christian Geßner, Brizio Moreno‐Jaime, Rodolfo Passalacqua, S. Li, Kristina McGuire, Ruben G.W. Quek, Giuseppe Gullo, Petra Rietschel

2021Annals of Oncology18 citationsDOIOpen Access PDF

Topics & Concepts

MedicineOncologyChemotherapyLung cancerLungInternal medicinePlatinumCatalysisBiochemistryChemistryLung Cancer Treatments and MutationsCancer Immunotherapy and BiomarkersCancer Genomics and Diagnostics
LBA51 EMPOWER-Lung 3: Cemiplimab in combination with platinum doublet chemotherapy for first-line (1L) treatment of advanced non-small cell lung cancer (NSCLC) | Litcius